TMEM30B Antibody

What is TMEM30B and why is it significant in cellular research?

TMEM30B (Transmembrane Protein 30B), also known as CDC50B or Cell cycle control protein 50B, functions as an accessory component of the P4-ATPase flippase complex. This protein plays a critical role in lipid transport and metabolism by catalyzing ATP hydrolysis coupled to aminophospholipid translocation across membrane leaflets . TMEM30B ensures the maintenance of asymmetric distribution of phospholipids, which is essential for membrane integrity and cellular function .

The significance of TMEM30B extends to:

• Phospholipid translocation implicated in vesicle formation

• Uptake of lipid signaling molecules

• Mediation of alpha subunit export (ATP8A1, ATP8B1, ATP8B2, and ATP8B4) from the endoplasmic reticulum to the plasma membrane

• Potential involvement in metabolic diseases and various cancers

TMEM30B has 2 transmembrane domains and an extracellular loop with 3 cysteines and an N-glycosylation site . Its gene is located on chromosome 14 and is highly conserved across species .

What are the key characteristics of commonly available TMEM30B antibodies?

TMEM30B antibodies are available in several formats with distinct characteristics:

Most TMEM30B antibodies are generated using synthesized peptides derived from the internal region of human TMEM30B . They are typically stored in phosphate buffered saline (pH 7.4) with 150mM NaCl, some containing 0.02% sodium azide and 50% glycerol .

How should TMEM30B antibodies be stored to maintain optimal activity?

For optimal maintenance of TMEM30B antibody activity, follow these research-validated storage protocols:

• Short-term storage (up to 1 week): Store at 2-8°C

• Long-term storage: Store at -20°C in small aliquots to prevent freeze-thaw cycles

• When shipping is required: Antibodies are typically shipped at 4°C

• Upon delivery: Aliquot immediately to minimize freeze-thaw cycles

• Avoid repeated freeze/thaw cycles as they can significantly reduce antibody efficacy and increase background signal

For reconstitution of lyophilized peptides (such as blocking peptides), use 0.1 ml DI water for a final concentration of 10 mg/ml .

What are the validated applications for TMEM30B antibodies in research?

TMEM30B antibodies have been validated for several research applications:

Western Blotting (WB): The primary validated application across most TMEM30B antibodies. Recommended dilutions typically range from 1:500 to 1:3000, depending on the specific antibody . Western blot analysis has been successfully performed on various cell extracts, including K562 cells and BxPC-3 and MCF7 cell lysates .

Enzyme-Linked Immunosorbent Assay (ELISA): Several antibodies are validated for ELISA with recommended dilutions ranging from 1:2000 to 1:40000 .

Immunocytochemistry: While less commonly validated, some antibodies may be suitable for immunocytochemistry applications, particularly for studying the subcellular localization of TMEM30B, which has been reported in the endoplasmic reticulum .

Blocking/Control Applications: Synthetic peptides corresponding to TMEM30B epitopes are available for use as blocking peptides in specificity controls .

What cell and tissue types are most suitable for TMEM30B expression studies?

Based on the research literature, these cell and tissue types are most suitable for TMEM30B expression studies:

Cell lines:

• K562 cells (human myelogenous leukemia cells)

• HEK293 and HK-2 cells (for overexpression studies)

• BxPC-3 and MCF7 cells (demonstrated in Western blot)

Tissues with reported endogenous expression:

• Pancreatic islets

• Kidney

• Prostate

Pathological tissues with altered expression:

When designing expression studies, consideration should be given to the reported subcellular localization of TMEM30B in the endoplasmic reticulum .

How should researchers optimize Western blotting protocols for TMEM30B detection?

For optimal Western blotting detection of TMEM30B, implement this methodological approach:

Sample Preparation:

• Lyse tissues or cells in RIPA buffer (50 mM Tris-HCl, 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS, pH 7.4)

• Supplement with Complete Protease Inhibitor Cocktail

• Determine protein concentration using DC Protein Assay or equivalent

Electrophoresis and Transfer:

• Separate equal amounts of protein on SDS polyacrylamide gels

• Transfer to PVDF membranes

• Block membranes with 8% non-fat dry milk in TBST for 2 hours at room temperature

Antibody Incubation:

• Primary antibody: Dilute TMEM30B antibody as recommended (typically 1:500-1:3000 for WB)

• Incubate overnight at 4°C

• Secondary antibody: Anti-rabbit HRP-conjugated (1:5000)

• Develop using ECL chemiluminescent substrate

Controls:

• Positive controls: K562, BxPC-3, or MCF7 cell lysates

• Loading controls: GAPDH or β-actin antibodies

• Specificity controls: Include blocking peptide controls when validating new antibodies

Optimization Tips:

• If high background occurs, increase dilution of primary antibody

• For weak signals, extend exposure time or decrease antibody dilution

• TMEM30B has a predicted molecular weight of approximately 38 kDa

How can researchers investigate TMEM30B's role in phospholipid translocation and membrane dynamics?

To investigate TMEM30B's role in phospholipid translocation and membrane dynamics, researchers should employ these advanced methodological approaches:

Fluorescence Recovery After Photobleaching (FRAP):

• Transiently transfect cells with GFP-tagged TMEM30B in both N- and C-terminal orientations

• Use GFP alone as a control for freely diffusing protein

• Use PKCa activated with PMA as a marker of slow-mobility membrane-associated protein

• FRAP analysis can confirm TMEM30B's membrane-bound status and assess its mobility

Protein-Protein Interaction Studies:

• Investigate interactions between TMEM30B and P4-ATPase flippase complex components

• Co-immunoprecipitation can identify binding partners

• The search results indicate TMEM30B interacts with ATP8A1, ATP8B1, ATP8B2, and ATP8B4

Phospholipid Translocation Assays:

• Utilize fluorescently labeled phospholipid analogs (e.g., NBD-PS, NBD-PE)

• Measure translocation rates in cells overexpressing or depleted of TMEM30B

• Compare with TMEM30A (CDC50A) for functional differences, as research indicates ATP8A2 assembles with CDC50A but not CDC50B (TMEM30B)

Cellular Localization Studies:

• Use antibodies against TMEM30B alongside markers for the ER (Calnexin), Golgi (GM130), and early endosomes (Rab11a)

• Employ super-resolution microscopy for detailed localization

• Both termini of TMEM30B face the cytoplasm, which is important for designing fusion protein constructs

What approaches should be used to study TMEM30B in disease contexts, particularly in cancer research?

For investigating TMEM30B in disease contexts, particularly cancer research, implement these specialized approaches:

Genetic Alteration Analysis:

• Investigate mutations and chromosomal aberrations in TMEM30B

• Research has identified potentially damaging mutations in TMEM30B and deletions in the TMEM30B locus in nearly 30% of ccRCC tumors

• Use database resources such as TCGA for analysis of genetic alterations

Functional Studies:

• Develop knockout or knockdown models for TMEM30B using CRISPR/Cas9 or RNAi

• Examine the effects on:

  • Cell proliferation and migration

  • Membrane lipid composition

  • ER stress responses (as seen with TMEM30A knockout, which indicated increased ER stress)

  • Export of alpha subunits from the ER to plasma membrane

Isoform-Specific Research:

• Design experiments to distinguish between TMEM30B isoforms

• Test isoform expression in different cancer types

• Consider the potential different functions of various isoforms

How can researchers address challenges with antibody specificity when studying proteins in the TMEM30 family?

Addressing antibody specificity challenges for TMEM30 family proteins requires these methodological approaches:

Validation Using Multiple Antibodies:

• Employ antibodies targeting different epitopes of TMEM30B

• Compare results across polyclonal and monoclonal antibodies

• Verify consistency in localization and expression patterns

Cross-Reactivity Assessment:

• The TMEM30 family includes TMEM30A, TMEM30B, and TMEM30C with potential structural similarities

• Test antibody specificity in systems where one family member is knocked out

• Perform peptide competition assays using specific blocking peptides

Recombinant Expression Systems:

• Overexpress tagged versions of each TMEM30 family member

• Test antibody reactivity against each overexpressed protein

• Use systems like HEK293 or HK-2 cells, which have been successfully used for TMEM30B overexpression studies

Advanced Specificity Controls:

• Include TMEM30B knockout or knockdown samples as negative controls

• Perform immunoprecipitation followed by mass spectrometry to confirm antibody targets

• Compare immunodetection patterns with known expression profiles of TMEM30 family members (TMEM30A is the most widely expressed β-subunit and interacts with 11 of the 14 mammalian P4-ATPases)

What factors might contribute to inconsistent results when using TMEM30B antibodies?

Several factors can contribute to inconsistent results when using TMEM30B antibodies:

Antibody Quality and Storage Issues:

• Degradation due to improper storage or excessive freeze-thaw cycles

• Lot-to-lot variability, particularly in polyclonal antibodies

• Solution: Aliquot antibodies upon receipt and store at -20°C; verify lot performance with positive controls

Sample Preparation Variables:

• Incomplete protein extraction from membranes (TMEM30B is a transmembrane protein)

• Protein degradation during sample processing

• Solution: Use appropriate lysis buffers containing detergents suitable for membrane proteins; add protease inhibitors

Expression Level Variations:

• TMEM30B expression varies across tissues and cell types

• Expression can be altered in disease states

• Solution: Include appropriate positive controls; adjust protein loading based on target abundance

Protocol Optimization Issues:

• Suboptimal antibody dilutions

• Insufficient blocking or washing

• Solution: Titrate antibody concentrations; optimize blocking conditions and washing steps

Cross-Reactivity Considerations:

• Potential cross-reactivity with other TMEM30 family members

• Solution: Validate specificity using blocking peptides; consider using recombinant monoclonal antibodies like EPR14409 for increased specificity

How should researchers evaluate discrepancies in TMEM30B localization or expression data across different studies?

When evaluating discrepancies in TMEM30B localization or expression data across studies, employ this systematic approach:

Methodological Analysis:

• Compare detection methods (antibody-based vs. mRNA-based approaches)

• Evaluate antibody characteristics (polyclonal vs. monoclonal, epitope locations)

• Assess cell/tissue preparation techniques that might affect membrane protein preservation

Context-Dependent Expression:

• TMEM30B is reported in endoplasmic reticulum , but localization could vary by:

  • Cell type and tissue origin

  • Disease state or stress conditions

  • Interactions with different P4-ATPases

Isoform Considerations:

• Different studies may detect different TMEM30B isoforms

• Verify which protein regions antibodies target relative to known isoforms

• Consider the possibility of alternatively spliced variants with different localization patterns

Experimental Design Analysis:

• Overexpression systems may show different localization than endogenous protein

• N- or C-terminal tags might affect trafficking or function

• The orientation of fusion proteins is important as both termini of TMEM30B face the cytoplasm

Data Integration Approach:

• Weight evidence based on methodological rigor

• Consider multiple lines of evidence (e.g., biochemical fractionation, imaging, functional assays)

• Acknowledge biological variability as a possible explanation for discrepancies

What advanced controls should be included when studying TMEM30B in the context of its interaction with P4-ATPases?

When studying TMEM30B interactions with P4-ATPases, these advanced controls are essential:

Co-expression Controls:

• Express TMEM30B alone as baseline control

• Co-express with known interacting partners (ATP8A1, ATP8B1, ATP8B2, ATP8B4)

• Include non-interacting P4-ATPase as negative control (e.g., ATP8A2 associates with CDC50A, not CDC50B/TMEM30B)

Domain-Specific Mutation Controls:

• Generate TMEM30B constructs with mutations in key interaction domains

• Create chimeric proteins between TMEM30A and TMEM30B to map interaction specificity

• Use deletions or point mutations that preserve structure but alter binding capacity

Subcellular Localization Controls:

• Track localization of both TMEM30B and P4-ATPases in the same cells

• Include markers for relevant compartments (ER, Golgi, plasma membrane)

• Use TMEM30A (CDC50A) as a comparison for localization patterns, as it mediates export of similar P4-ATPases

Functional Readout Controls:

• Measure phospholipid flipping activity with each interaction pair

• Include catalytically inactive P4-ATPase mutants

• Compare lipid substrate specificity between different TMEM30B-P4-ATPase pairs

Temporal Controls:

• Monitor protein interaction and localization over time

• Assess effects of cellular stressors or lipid environment changes

• Include cell-cycle-dependent analysis (given the alternative name "Cell cycle control protein 50B")

How might TMEM30B be involved in neurological disorders and what experimental approaches should be used to investigate this connection?

The potential involvement of TMEM30B in neurological disorders warrants exploration through these experimental approaches:

Expression Analysis in Neurological Tissues:

• While TMEM30A disruption has been linked to cerebellar ataxia and Purkinje cell death , TMEM30B's neurological role requires investigation

• Compare TMEM30B expression in normal and pathological brain tissues

• Analyze expression across different neural cell types (neurons, astrocytes, oligodendrocytes)

Animal Model Development:

• Consider conditional knockout models targeting TMEM30B in specific neural populations

• Compare phenotypes with TMEM30A knockout models, which show early-onset ataxia and progressive Purkinje cell death

• Assess behavioral, electrophysiological, and morphological consequences

Lipid Dynamics in Neural Membranes:

• Investigate TMEM30B's role in maintaining phospholipid asymmetry in neural membranes

• Assess impact on myelin formation and stability

• Explore potential roles in synaptic vesicle cycling and neurotransmitter release

ER Stress and Neural Degeneration Connection:

• Evaluate whether TMEM30B deficiency induces ER stress in neural cells similar to TMEM30A

• Measure expression of stress markers (CHOP, BiP) in TMEM30B-deficient neural tissues

• Investigate potential apoptotic mechanisms using TUNEL analysis and cleaved caspase-3 immunostaining

P4-ATPase Partners in Neural Tissues:

• Identify which P4-ATPases partner with TMEM30B in neural tissues

• Compare with TMEM30A-associated P4-ATPases

• Investigate whether mutations in neurological disorders affect these interactions

What are the most promising approaches for studying the role of TMEM30B in lipid metabolism disorders?

For investigating TMEM30B in lipid metabolism disorders, these approaches show the greatest promise:

Lipidomic Profiling:

• Perform comprehensive lipidomic analysis in systems with altered TMEM30B expression

• Compare membrane phospholipid composition and asymmetry

• Identify specific lipid species most affected by TMEM30B alterations

Metabolic Disease Models:

• Develop TMEM30B knockout or overexpression models in metabolically relevant tissues

• Study effects on:

  • Obesity and insulin resistance

  • Cardiovascular disease models

  • Non-alcoholic fatty liver disease

• TMEM30B has been implicated in various metabolic diseases and is a promising target for therapeutic intervention

Lipid Transport Kinetics:

• Measure rates of specific phospholipid flipping in cellular models

• Compare kinetics between wild-type and mutant TMEM30B

• Assess competitive effects of various lipid substrates

Therapeutic Targeting Approaches:

• Develop screening assays for compounds that modulate TMEM30B-P4-ATPase interactions

• Investigate whether existing lipid-modulating drugs affect TMEM30B function

• Explore RNA-based therapeutics for modulating TMEM30B expression

Clinical Correlation Studies:

• Analyze TMEM30B expression or genetic variants in patients with lipid metabolism disorders

• Correlate findings with clinical parameters and treatment responses

• Search for potential biomarkers based on TMEM30B function or expression

What new technological developments might advance our understanding of TMEM30B structure-function relationships?

Emerging technologies offer promising avenues for advancing TMEM30B structure-function research:

Cryo-Electron Microscopy (Cryo-EM):

• Determine high-resolution structures of TMEM30B alone and in complex with P4-ATPases

• Visualize conformational changes during the catalytic cycle

• Compare structural features with other CDC50 family members

• Current structural models (like ModBase) provide only preliminary insights

Proximity Labeling Proteomics:

• Employ BioID or APEX2 fusion proteins to identify proximal interactors of TMEM30B

• Map the protein interaction network in different cellular compartments

• Compare interactomes across different cell types and disease states

Live-Cell Super-Resolution Microscopy:

• Track TMEM30B dynamics in real-time using techniques like PALM or STORM

• Visualize interactions with P4-ATPases at nanometer resolution

• Monitor phospholipid translocation events in parallel with protein localization

CRISPR-Based Genome Editing:

• Generate precise point mutations to test structure-function hypotheses

• Create endogenously tagged versions of TMEM30B to avoid overexpression artifacts

• Develop inducible systems to study acute loss or gain of function

Molecular Dynamics Simulations:

• Model TMEM30B interactions with membrane lipids and P4-ATPases

• Predict effects of disease-associated mutations on protein stability and function

• Simulate conformational changes during the phospholipid flipping process